Adebrelimab plus chemotherapy and sequential thoracic radiotherapy as first-line therapy for extensive-stage small–cell lung cancer (ES-SCLC): a phase II trial
This study was funded by the National Natural Science Foundation of China (82172865), Jiangsu Hengrui Pharmaceuticals Co., Ltd. and Amoy Diagnostics Co., Ltd.
Authors
- Xudong Hu
- Xiangjiao Meng (ORCID: https://orcid.org/0000-0001-7380-5510)
- Changhong Zhao (ORCID: https://orcid.org/0000-0003-0539-8591)
- Jiajia Yuan
- Pinliang Zhang
- Bing Zou (ORCID: https://orcid.org/0000-0001-9941-4796)
- Aiqin Gao (ORCID: https://orcid.org/0000-0003-1157-6104)
- Butuo Li (ORCID: https://orcid.org/0000-0002-1849-3435)
- Jinming Yu (ORCID: https://orcid.org/0000-0001-7710-5466)
- Qian Li (ORCID: https://orcid.org/0000-0002-2507-3914)
- Jun Guo (ORCID: https://orcid.org/0000-0002-4630-9033)
- Dawei Chen (ORCID: https://orcid.org/0000-0002-6762-7997)
- Linlin Wang (ORCID: https://orcid.org/0000-0002-2231-6642)
- Qian Shao (ORCID: https://orcid.org/0000-0002-1002-380X)
- Wei Huang (ORCID: https://orcid.org/0000-0003-3020-2079)
- Changbin Zhu
- Xiaoyong Tang
- Yan Zhang (ORCID: https://orcid.org/0000-0002-4835-8541)
Institutions
- Shandong Tumor Hospital (CN)
- Jiangsu Hengrui Medicine (China) (CN)
- Dian Diagnostics (China) (CN)
- Shandong First Medical University (CN)
- Xiamen Tobacco Industry (China) (CN)
Publication Details
- Journal
- EClinicalMedicine
- Published
- 2024-08-23
- DOI
- https://doi.org/10.1016/j.eclinm.2024.102795
- Citations
- 28
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 7.91
Funders
- Jiangsu Hengrui Medicine
- National Natural Science Foundation of China